Table 3.
Analysis of the Prognostic Role of VEGFAxxx and VEGFA165b Expression in HNSCC
| 12-month disease-free survival (%) | p value | 12-month overall survival (%) | p value | |
|---|---|---|---|---|
| VEGFAxxx | ||||
| Overexpression | 75 | 0.963 | 100 | 0.902 |
| Down expression | 81 | 90 | ||
| VEGFA165b | ||||
| Overexpression | 75 | 0.687 | 100 | 0.91 |
| Down expression | 79 | 100 | ||